Armentum Partners
VC Fund
San Francisco, United States
Armentum Partners is a financial services firm focused on providing debt capital raising solutions to technology and healthcare companies.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 9%
Last updated:
For AI agents: llms.txt
Industries Armentum Partners invests in
Health CareBiotechnologyMedicalMedical DeviceTherapeutics
Stages Armentum Partners invests in
Debt FinancingPost-IPO DebtFunding Round
Countries Armentum Partners invests in
United StatesCanadaGermanyIsraelAustria
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chris Carthy
|
|||
Investment Focus
Industry
- Health Care 20 (61%)
- Biotechnology 15 (45%)
- Medical 11 (33%)
- Medical Device 7 (21%)
- Therapeutics 5 (15%)
Stage
- Debt Financing 22 (67%)
- Post-IPO Debt 10 (30%)
- Funding Round 1 (3%)
Country
- United States 23 (70%)
- Canada 3 (9%)
- Germany 3 (9%)
- Israel 1 (3%)
- Austria 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chris Carthy
Managing Partner & Founder
|
Managing Partner & Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Groups Recover Together
|
Groups Recover Together was founded to make treatment for opioid addiction respectful, accessible, and affordable. We empower our members to regain control of their lives through a proven, evidence-based model of medication-assisted treatment (MAT) with buprenorphine and weekly group therapy. | $55M / Debt Financing / Jan 01, 2023 | |
Lucira Health
|
Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries andfits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. | $80M / Post-IPO Debt / Feb 04, 2022 | |
Tarsus Pharmaceuticals
|
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases acrosstherapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis. | $175M / Post-IPO Debt / Jan 01, 2022 | |
KOHO Financial
|
KOHO Financial provides an application based banking platform intended to simplify financial products available to everyone. Its platform helps users to complete their day to day banking operations while offering tools such as goals, cash flow projections, group spending, spending insights, and categorizations, enabling users to manage theirexpenses and banking operations on the go. | $65M / Debt Financing / Jan 01, 2022 | |
Viome
|
Viome is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age. The company's insights help users to make suitable lifestyle and nutrition choices for them, enabling users to assess their internal eco-system with simple personalizedrecommendations.Viome was established on October 1, 2016 by Naveen Jain in Bellevue, Washington. | $20M / Debt Financing / Jan 01, 2022 | |
BlueWind Medical
|
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral neuropathic pain (PNP). | Debt Financing / Jan 01, 2022 | |
Coherus Biosciences
|
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, andclinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. | $400M / Post-IPO Debt / Jan 01, 2022 | |
Apeel Sciences
|
Apeel Sciences produces products including avocados, apples, mangos, cucumbers, and citrus protected by plants. They support the plant’s natural ability to protect against environmental stress by maintaining moisture and reducing oxidation. | $75M / Debt Financing / Jan 01, 2022 | |
SellerX
|
SellerX buys and grows Amazon businesses. We are a VC-backed start-up with a growing, diversified portfolio of FBA (Fulfillment by Amazon) sellers. Our goal is to optimize and grow the brands we acquire post-acquisition.Founded by two HBS graduates: one who built an e-commerce business to $1bn+ in revenue as co-founder, and the other a formerGoldman Sachs SSG with extensive PE roll-up experience. Together, they have raised over $250mn in financing led by L Catterton, Cherry Ventures, Felix Capital, 83 North and Silicon Valley-based TriplePoint Capital. | Debt Financing / Dec 09, 2021 | |
Eloxx
|
Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsensemutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others.Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases. | $30M / Post-IPO Debt / Oct 05, 2021 | |
| See all 33 investments → | |||
Co-Investors
Hercules Capital
3 deals together
Oxford Finance LLC
2 deals together
ATEL Growth Capital
1 deal together
Athyrium Capital Management LP
1 deal together
Espresso Capital
1 deal together
First Analysis
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Armentum Partners invest in?
Armentum Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 33 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Armentum Partners?
Public channels for Armentum Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Armentum Partners?
The team at Armentum Partners includes Chris Carthy (Managing Partner & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
